Navigation Links
Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
Date:9/27/2007

NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Paramount Acquisition Corp. (OTC Bulletin Board: PMQC, PMQCU, PMQCW), a special purpose acquisition corporation ("SPAC"), announced today the filing of a third amendment to the preliminary proxy statement with the Securities and Exchange Commission (SEC) that was originally filed on June 18, 2007. The amended preliminary proxy statement is for a special meeting of stockholders to be held to consider the previously announced acquisition of Chem Rx, a major privately-owned long-term care pharmacy based in Long Beach, New York.

Once the SEC reviews and clears the preliminary proxy statement, Paramount will mail a definitive proxy statement to its stockholders of record on October 1, 2007. The date of the special meeting of stockholders will be announced in advance of the mailing of the definitive proxy statement. For stockholders' general information, the preliminary proxy statement is available from the SEC's website at http://www.sec.gov. Assuming all conditions of the transaction are met, Paramount anticipates completing the transaction on or prior to October 26, 2007.

ABOUT CHEM RX

Founded more than 40 years ago, Chem Rx is a major, privately-owned long- term care pharmacy serving the New York City metropolitan area, as well as parts of New Jersey, upstate New York, and Pennsylvania. Chem Rx's client base includes skilled nursing facilities and a wide range of other long-term care facilities. Chem Rx provides to more than 61,000 residents prescription and non-prescription drugs, intravenous medications, durable medical equipment items and surgical supplies. Chem Rx's website address is http://www.chemrx.net.

ABOUT PARAMOUNT ACQUISITION CORP.

Paramount Acquisition Corp. is a special purpose acquisition corporation that was formed for the specific purpose of effecting a merger, capital stock exchange, asset acquisition, or other similar business combination with an operating business in the healthcare industry. Paramount raised net proceeds of approximately $53 million through its initial public offering consummated in October 2005 and exercise of the over-allotment option, and has dedicated its attention since the offering to seeking and evaluating business combination opportunities.

Paramount Acquisition Corp. is an affiliate of Paramount BioSciences, LLC, which focuses primarily on the development of promising in-licensed drug candidates. Founded in 1991 by Lindsay A. Rosenwald, M.D., Paramount BioSciences is a unique drug development and health care financial company that, with the assistance of its affiliated life sciences merchant bank, has created approximately 50 start-up companies over the past fifteen years, about half of those over the past four years alone. Since its inception, Paramount BioSciences and its affiliated companies have been involved in the clinical development of more than seventy drug candidates -- several of which have reached the market -- and have over forty compounds in clinical development today. Paramount BioSciences has extensive experience in all facets of the development of emerging life sciences companies and provides its portfolio companies a wide range of professional and financial support services.

Cautionary Statements

This press release contains forward-looking statements about Paramount, Chem Rx and their combined business after completion of the proposed business combination. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of Paramount's or Chem Rx's management and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward- looking statements: compliance with government regulations; changes in legislation or regulatory environments; requirements or changes adversely affecting the health care industry, including changes in Medicare reimbursement policies; fluctuations in customer demand; management of rapid growth; intensity of competition; timing, approval and market acceptance of new product introductions; general economic conditions; geopolitical events and regulatory changes, as well as other relevant risks detailed in Paramount's filings with the SEC, including its Annual Report on Form 10-KSB for the year ended December 31, 2006. The information set forth herein should be read in light of such risks. Paramount does not assume any obligation to update the information contained in this press release.

Additional information concerning the transaction is included in the preliminary proxy statement originally filed by Paramount with the SEC on June 18, 2007, and amended on August 13, 2007, September 12, 2007 and September 27, 2007, and the Current Report on Form 8-K originally filed on June 4, 2007, and amended on July 2, 2007, by Paramount with the SEC. STOCKHOLDERS OF PARAMOUNT AND OTHER INTERESTED PERSONS ARE ADVISED TO READ THE PRELIMINARY PROXY STATEMENT AND, WHEN AVAILABLE, PARAMOUNT'S DEFINITIVE PROXY STATEMENT IN CONNECTION WITH THE SOLICITATION OF PROXIES FOR THE SPECIAL MEETING BECAUSE THESE PROXY STATEMENTS WILL CONTAIN IMPORTANT INFORMATION. Such persons may also read Paramount's final prospectus, dated October 21, 2005, as well as its periodic reports for more information about Paramount, its officers and directors and their interests in a successful completion of a business combination. The definitive proxy statement will be mailed to stockholders as of October 1, 2007. Stockholders will also be able to obtain a copy of the definitive proxy statement, without charge, once available, as well as Paramount's final prospectus and periodic reports, at the SEC's Internet site http://www.sec.gov or by directing a request to Paramount Acquisition Corp., 787 7th Avenue, 48th Floor, New York, NY 10019. As a result of the review by the SEC of the preliminary proxy statement, Paramount may be required to make changes to its description of Chem Rx's business or other information contained in the proxy statement.

Paramount, Chem Rx and their respective officers and directors may be deemed to be participants in the solicitation of proxies from Paramount's stockholders with respect to the transaction. More detailed information regarding the direct and indirect interests of Paramount, Chem Rx and their respective officers and directors in the proposed transaction are included in the proxy statement.

Contacts:

J. Jay Lobell Stephanie Carrington / Elizabeth Scott

Chief Executive Officer & The Ruth Group

Secretary 646-536- 7017 / 7014

Paramount Acquisition Corp. scarrington@theruthgroup.com

(212) 554-4522 escott@theruthgroup.com

jlobell@paramountbio.com


'/>"/>
SOURCE Paramount Acquisition Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
2. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
3. NHS financial crisis may lead to roll back of flexi-work scheme and private acquisition
4. Smoking Increases Risk of HIV Acquisition
5. Roche Completes Acquisition of BioVeris
6. Circassia Announces Acquisition of Organ Transplant Anti-Rejection Technology
7. Oracle Corp. to help build worlds first "Digital Hospital"
8. Novartis files application with FDA for Zometa
9. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
10. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
11. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. ... line of probiotics, Petbiotics ™, as they fondly call them. As animal ... groups networking for their non-profit organizations. Animal rescues across the nation face huge ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in ... efficacy of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... 2014. Each year, reproductive endocrinologists are required to report in vitro fertilization ... of professionals dedicated to the practice of assisted reproductive technologies in the United ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
Breaking Medicine Technology: